Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Six-month trial results show Lumigan clinically superior to timolol in lowering IOP

March 6, 2001

Japanese patent issued to Santen for new agents for glaucoma

March 1, 2001

Statistically significant phase II results reported for INS-365 Ophthalmic

Feb. 28, 2001

Santen granted rights to develop and market lomerizine for ophthalmological indications

Feb. 27, 2001

Promising data reported for Visudyne in occult AMD and pathological myopia

Feb. 14, 2001

GenVec to apply PEDF technology to the treatment of blindness

Feb. 13, 2001

FDA issues approvable letter for Visudyne

Feb. 5, 2001

Clearance sought to begin clinical trials with INS-37217 Ophthalmic

Feb. 2, 2001

Clinical evaluation of Envision TD for DME and posterior uveitis continues

Jan. 26, 2001

New ROCK inhibitor with potential for the treatment of glaucoma licensed out by Welfide

Jan. 25, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...